argenx SE (ARGX) is in Healthcare, Biotechnology, based in Netherlands, listed on NasdaqGS. Market cap 51.48B USD. 52-week range 661.85 to 1,072.75 USD. Trailing P/E 31.2. Data as of 2026-10-09.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, ...